Co-Diagnostics, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. Co-Diagnostics, Inc. was incorporated in 2013 and is based in Salt Lake City, Utah.
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-14upcoming | -3.00 | — | — |
| 2026-05-14 | -3.75 | -4.09 | -9.05% |
| 2026-03-31 | -3.60 | -4.44 | -23.30% |
| 2025-11-13 | -5.70 | -4.66 | +18.21% |
| 2025-08-14 | -7.50 | -7.01 | +6.60% |
| 2025-05-08 | -9.90 | -7.72 | +22.00% |
| 2025-03-27 | -10.20 | -11.33 | -11.12% |
| 2024-11-07 | -9.90 | -9.82 | +0.82% |
| 2024-08-08 | -10.20 | -7.33 | +28.16% |
| 2024-05-09 | -6.30 | -9.81 | -55.76% |
| 2024-03-14 | -6.00 | -15.00 | -150.00% |
| 2023-11-09 | -8.70 | -6.54 | +24.83% |
| 2023-08-10 | -7.20 | -9.50 | -31.87% |
| 2023-05-11 | -7.20 | -6.91 | +4.00% |
| 2023-03-16 | -4.50 | -6.07 | -34.87% |
| 2022-11-10 | -1.00 | -2.38 | -138.20% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| CODX | +450.32% | +282.51% | +68.24% | +11.07% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +447.35% | +287.15% | +71.69% | -1.62% |